Se connecter Inscription gratuite

Financière de Tubize SA VE/BAIIA

Quel est le VE/BAIIA de Financière de Tubize SA?

Le VE/BAIIA de Financière de Tubize SA est 9.74

Quelle est la définition de VE/BAIIA?



VE/BAIIA est la valeur de l’entreprise divisée par le bénéfice avant intérêts, impôts, dépréciations et amortissements. Il s'agit d'une mesure du coût d'une action et est plus souvent valable pour des comparaisons entre sociétés que le ratio cours / bénéfice. Il mesure le prix (sous forme de valeur d'entreprise) qu'un investisseur paie au profit des flux de trésorerie de l'entreprise (sous forme de BAIIA).

Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.

VE/BAIIA des entreprises dans Health Care secteur sur EURONEXT par rapport à Financière de Tubize SA

Que fait Financière de Tubize SA?

Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.

Entreprises avec ve/baiia similaire à Financière de Tubize SA